PA

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Goldhahn J et al. – There is no evidence–based reason to withhold anti–resorptive therapy while a fracture heals, whether or not the patient was taking such therapy when the fracture occurred. The workshop also considered existing models of service provision for secondary prevention and concluded that the essential ingredient for reliable delivery is the inclusion of a dedicated coordinator role. Several unresolved issues were defined as subjects for further research, including the question of whether continuous long–term administration of anti–resorptives may impair bone quality.

   

Related Articles

Osteologix to Continue Development of Osteoporosis Drug
Internet Source, 10/21/09    Relevance Score: 93%

Lifestyle increases osteoporosis risk: docs
Internet Source, 10/21/09    Relevance Score: 90%

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
Clinical Interventions in Aging, 11/12/09    Relevance Score: 89%

A microarray based identification of osteoporosis-related genes in primary culture of human osteoblasts
Bone, 10/27/09    Relevance Score: 89%

Evaluation of Compliance with Osteoporosis Treatment Guidelines After Initiation of a Pharmacist-Run Osteoporosis Service at a Family Medicine Clinic
Annals of Pharmacotherapy, 10/15/09    Relevance Score: 89%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address